Imatinib 100mg Capsules

Imatinib 100mg Capsules is the groundbreaking “first-in-class” tyrosine kinase inhibitor (TKI) that fundamentally changed the landscape of cancer treatment, turning fatal diagnoses into manageable chronic conditions. Often described as the “magic bullet” of oncology, this targeted therapy works by specifically inhibiting the Bcr-Abl tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome found in Chronic Myeloid Leukemia (CML). By binding to the ATP-binding pocket of this enzyme, the medication physically blocks the transfer of energy (phosphorylation) required for the cancer cell to signal growth and division. This precise blockade effectively shuts down the proliferation of leukemia cells and induces apoptosis (programmed cell death) while largely sparing healthy cells. Additionally, it exerts powerful inhibitory effects on other receptor tyrosine kinases such as c-KIT and PDGFR, extending its therapeutic reach to gastrointestinal and blood disorders. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for achieving deep molecular remission, offering patients a life-saving oral alternative to bone marrow transplantation.

The 100mg capsule strength is a critical formulation for precise dose titration. While the standard adult dose for chronic phase CML is typically 400mg (4 capsules) daily, the 100mg unit allows oncologists to adjust the regimen for pediatric patients, those with renal or liver impairment, or patients experiencing manageable toxicity. This flexibility is essential for maintaining long-term adherence to this life-extending therapy.

Indications / Uses of Imatinib 100mg Capsules

This product is commonly prescribed for the specialized management of the following malignancies:

• Chronic Myeloid Leukemia (CML): It is the gold-standard first-line treatment for adult and pediatric patients with Philadelphia chromosome-positive (Ph+) CML in chronic phase, as well as for accelerated phase or blast crisis.
• Gastrointestinal Stromal Tumors (GIST): The medication is indicated for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant GIST, and as adjuvant treatment following surgical removal of significant tumors.
• Acute Lymphoblastic Leukemia (ALL): It is used in combination with chemotherapy for adult and pediatric patients with Ph+ Acute Lymphoblastic Leukemia.
• Myelodysplastic/Myeloproliferative Diseases (MDS/MPD): Indicated for adult patients with MDS/MPD associated with PDGFR gene re-arrangements.

Key Features

• Targeted Bcr-Abl Inhibition: The primary feature of the medication is its specificity for the mutant kinase driven by the Philadelphia chromosome, addressing the root genetic cause of the cancer.
• High Molecular Response: Clinical data shows that the therapy can reduce the level of leukemia cells to undetectable levels (Major Molecular Response) in a significant percentage of patients.
• Dual-Action Utility: It effectively targets both Bcr-Abl in leukemia and c-KIT in gastrointestinal tumors.
• Oral Convenience: The capsule form allows for home-based management, eliminating the need for hospital stays associated with older chemotherapy regimens.
• Established Safety Profile: With decades of clinical use, the long-term safety and management of side effects are well-understood by clinicians.

Storage for Imatinib 100mg Capsules

To preserve the pharmacological stability and ultimate potency of the active ingredients, the capsules should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F to 86°F). It is vital to protect the medication from moisture; keep the bottle tightly closed. For maximum safety, always store the product in a secure, high location that is strictly out of the reach and sight of children and pets.

Important Note on Imatinib 100mg Capsules

The administration of Imatinib 100mg Capsules requires specific dietary habits to minimize gastrointestinal irritation. The capsules must be taken with a meal and a large glass of water. Taking the medication on an empty stomach frequently causes significant nausea and vomiting.

Fluid Retention (Edema) is a hallmark side effect; patients often experience swelling around the eyes (periorbital edema) or in the legs. While usually manageable, severe fluid retention (pleural effusion, pericardial effusion) can occur, so unexpected rapid weight gain or shortness of breath should be reported immediately.

Muscle Cramps and bone pain are also common. The drug is metabolized by the liver (CYP3A4); therefore, patients must avoid grapefruit and grapefruit juice, which can dangerously increase drug levels. Potential hepatotoxicity implies that liver function tests should be monitored. Imatinib 100mg Capsules can cause fetal harm (Pregnancy Category D); effective contraception is mandatory. By strictly following these professional guidelines and taking the dose with food, patients can safely maximize the therapeutic success of this pioneering drug.